Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition

Plasma Omega-3 Status Clinical Trial

Official title:

Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03245749
• Other study ID #: RRD7/N02/A
• Status: Completed
• Start date: June 2003
• Est. completion date: March 2006

Study information

• Verified date: July 2021
• Source: University of Southampton
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate the effect of habitual oily fish intake, sex, age, BMI, and APOE genotype on plasma long chain n-3 fatty acid composition.

Description:

The marine long chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial to cardiovascular and cognitive health and the concentration of EPA and DHA present in blood and tissue lipids is positively correlated with these effects.

As a result, national and global authorities recommend regular consumption of oily fish in order to provide approximately 500 mg EPA+DHA per day in a healthy population. However, the associations between EPA and DHA intake and blood and tissue status, and therefore physiological benefits, are highly variable and the factors influencing this heterogeneity are not well understood.

This study aims to investigate the effect of habitual oily fish intake as well as sex, age, BMI, and Apolipoprotein E (APOE) genotype on LC n-3 PUFA status in plasma phosphatidylcholine, non-esterified fatty acids, cholesteryl esters and triacylglycerols in order to obtain greater knowledge of the determinants of LC n-3 PUFA status with the potential to develop more robust, and perhaps subgroup specific, recommendations for EPA and DHA intake.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 374
• Est. completion date: March 2006
• Est. primary completion date: September 2005
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Exclusion Criteria:

• Diagnosed endocrine dysfunction including diabetes

• Fasting glucose concentration > 6.5 mmol/L

• Myocardial infarction in the previous 2 years

• The use of medication that may interfere with lipid metabolism

• Fasting total cholesterol of > 8.0 mmol/L

• TG of > 3.0 mmol/L

• Currently following a weight loss diet

• Taking n-3 fatty acid supplements

Related Conditions & MeSH terms

• Plasma Omega-3 Status

Locations

Country	Name	City	State
United Kingdom	University of Glasgow	Glasgow
United Kingdom	Newcastle University	Newcastle upon Tyne
United Kingdom	Univeristy of East Anglia	Norwich
United Kingdom	University of Reading	Reading
United Kingdom	University of Southampton	Southampton

Sponsors (3)

Lead Sponsor	Collaborator
University of Southampton	Food Standards Agency, United Kingdom, Ocean Nutrition

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Fisk HL, Irvine M, Miles EA, Lietz G, Mathers JC, Packard CJ, Armah CK, Kofler BM, Curtis PJ, Minihane AM, Calder PC. Association of oily fish intake, sex, age, BMI and APOE genotype with plasma long-chain n-3 fatty acid composition. Br J Nutr. 2018 Jul;1 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma long chain n-3 polyunsaturated fatty acid concentrations	Concentrations of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) in plasma phosphatidylcholine, non-esterified fatty acids, cholesteryl esters and triacylglycerols	Baseline
Secondary	APOE genotyping	APOE genotype determined from blood sample	Baseline
Secondary	Anthropometric measurements	Height and weight to determine BMI	Baseline